4-溴-2,3,5-三甲基吡啶1-氧化物 | 848694-11-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 4-溴-2,3,5-三甲基吡啶1-氧化物
• 英文名称: 4-bromo-2,3,5-collidine N-oxide
• 英文别名: 4-bromo-2,3,5-trimethylpyridine-N-oxide；4-bromo-2,3,5-trimethylpyridine 1-oxide；4-bromo-2,3,5-trimethyl-1-oxidopyridin-1-ium
• CAS: 848694-11-1
• 化学式: C₈H₁₀BrNO
• 分子量: 216.077
• InChiKey: XJTFVTIYKKOOCN-UHFFFAOYSA-N

物化性质

• 沸点：
  366.3±37.0 °C(Predicted)
• 密度：
  1.43±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  25.5
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-溴-2,3,5-三甲基吡啶1-氧化物 在 间氯过氧苯甲酸 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 16.17h， 生成 acetic acid 4-methanesulfinyl-3,5-dimethylpyridin-2-ylmethyl ester
  参考文献：
  名称：

  Rationally Designed High-Affinity 2-Amino-6-halopurine Heat Shock Protein 90 Inhibitors That Exhibit Potent Antitumor Activity

  摘要：

  Heat shock protein 90 (Hsp90) is a molecular chaperone protein implicated in stabilizing the conformation and maintaining the function of many cell-signaling proteins. Many oncogenic proteins are more dependent on Hsp90 in maintaining their conformation, stability, and maturation than their normal counterparts. Furthermore, recent data show that Hsp90 exists in an activated form in malignant cells but in a latent inactive form in normal tissues, suggesting that inhibitors selective for the activated form could provide a high therapeutic index. Hence, Hsp90 is emerging as an exciting new target for the treatment of cancer. We now report on a novel series of 2-amino-6-halopurine Hsp90 inhibitors exemplified by 2-amino-6-chloro-9-(4-iodo-3,5-dimethylpyridin-2-ylmethyl)purine (30). These highly potent inhibitors (IC50 of 30 = 0.009 mu M in a HER-2 degradation assay) also display excellent antiproliferative activity against various tumor cell lines (IC50 of 30 = 0.03 mu M in MCF7 cells). Moreover, this class of inhibitors shows higher affinity for the activated form of Hsp90 compared to our earlier 8-sulfanylpurine Hsp90 inhibitor series. When administered orally to mice, these compounds exhibited potent tumor growth inhibition (> 80%) in an N87 xenograft model, similar to that observed with 17-allylamino-17-desmethoxygeldanamycin (17-AAG), which is a compound currently in phase I/II clinical trials.

  DOI：

  10.1021/jm050752+
• 作为产物：
  描述：

  2,3,5-三甲基吡啶 1-氧化物 在 sodium bromate 、 硫酸 、 sodium bromide 作用下， 以 水 为溶剂， 反应 15.0h， 生成 4-溴-2,3,5-三甲基吡啶1-氧化物
  参考文献：
  名称：

  一种4-甲氧基-2,3,5-三甲基-吡啶氮氧化物的合成方法

  摘要：

  本发明公开了一种4‑甲氧基‑2,3,5‑三甲基‑吡啶氮氧化物的合成方法，包括以下步骤：S1、2,3,5‑三甲基吡啶‑N‑氧化物经溴代反应、甲氧基取代得到4‑溴‑2,3,5‑三甲基‑吡啶氮氧化物；S2、4‑溴‑2,3,5‑三甲基‑吡啶氮氧化物经甲醇钠取代反应生成奥美拉唑的重要中间体4‑甲氧基‑2,3,5‑三甲基‑吡啶氮氧化物。本发明工艺路线中先采用了溴酸盐和溴化盐这种温和的溴化反应条件，然后再利用溴代物中间体进行甲氧基取代反应，整个工艺设计简单，反应条件温和，操作简便易行。

  公开号：

  CN112645873A

文献信息

• 2-Aminopurine analogs having HSP90-inhibiting activity
  申请人：Kasibhatla Rao Srinivas

  公开号：US20050113340A1

  公开（公告）日：2005-05-26

  2-Aminopurine analogs are described and demonstrated or predicted to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents in the treatment and prevention of various HSP90 mediated disorders, e.g., proliferative disorders. Method of synthesis and use of such compounds are also described and claimed.

  本文描述了2-氨基嘌呤类似物，并展示或预测其作为热休克蛋白90（HSP90）抑制剂，在治疗和预防各种HSP90介导的疾病，例如增殖性疾病方面具有实用性。还描述和声明了这些化合物的合成方法和使用方法。
• Pyrrolopyrimidines and related analogs as HSP90-inhibitors
  申请人：Kasibhatla R. Srinivas

  公开号：US20050107343A1

  公开（公告）日：2005-05-19

  Pyrrolopyrimidines and related analogs are described and demonstrated to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents used in the treatment and prevention of various HSP90 mediated disorders, e.g., proliferative disorders. Methods of synthesis and use of such compounds are also described and claimed.

  本文描述了吡咯并嘧啶及其相关类似物作为热休克蛋白90（HSP90）抑制剂在治疗和预防各种HSP90介导的疾病，例如增生性疾病方面的用途。同时还描述和声明了这些化合物的合成和使用方法。
• Pyrazolopyrimidines and related analogs as HSP90-inhibitors
  申请人：Kasibhatla Rao Srinivas

  公开号：US20050119282A1

  公开（公告）日：2005-06-02

  Pyrazolopyrimidines and related analogs are described and demonstrated or predicted to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents in the treatment and prevention of various HSP90 mediated disorders, e.g., proliferative disorders. Method of synthesis and use of such compounds are also described and claimed.

  本文描述了吡唑吡咯啉和相关类似物，证明或预测其在治疗和预防各种HSP90介导的疾病，例如增生性疾病中作为HSP90抑制剂的效用。同时还描述和声明了这些化合物的合成方法和用途。
• 2-aminopurine analogs having HSP90-inhibiting activity
  申请人：Conforma Therapeutics Corporation

  公开号：US07138401B2

  公开（公告）日：2006-11-21

  2-Aminopurine analogs are described and demonstrated or predicted to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents in the treatment and prevention of various HSP90 mediated disorders, e.g., proliferative disorders. Method of synthesis and use of such compounds are also described and claimed.

  描述了2-氨基嘌呤类似物，并证明或预测其在治疗和预防各种HSP90介导的疾病，例如增殖性疾病中作为热休克蛋白90（HSP90）抑制剂的效用。还描述和声明了这些化合物的合成方法和用途。
• Pyrrolopyrimidines and Related Analogs as HSP90-Inhibitors
  申请人：Kasibhatla R. Srinivas

  公开号：US20070173483A1

  公开（公告）日：2007-07-26

  Pyrrolopyrimidines and related analogs are described and demonstrated to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents used in the treatment and prevention of various HSP90 mediated disorders, e.g., proliferative disorders. Methods of synthesis and use of such compounds are also described and claimed.

  本文描述并证明吡咯并嘧啶及相关类似物作为热休克蛋白90（HSP90）抑制剂在治疗和预防各种HSP90介导的疾病中具有效用，例如增殖性疾病。本文还描述和声明了这些化合物的合成和使用方法。